G2ME34 Stock Overview
A medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Globus Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$50.35 |
| 52 Week High | US$69.72 |
| 52 Week Low | US$47.48 |
| Beta | 1.19 |
| 1 Month Change | -15.49% |
| 3 Month Change | -19.62% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 27.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| G2ME34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | -9.2% | -3.0% | 2.1% |
| 1Y | n/a | 1.6% | -5.5% |
Return vs Industry: Insufficient data to determine how G2ME34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how G2ME34 performed against the BR Market.
Price Volatility
| G2ME34 volatility | |
|---|---|
| G2ME34 Average Weekly Movement | 5.7% |
| Medical Equipment Industry Average Movement | 6.0% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in BR Market | 9.5% |
| 10% least volatile stocks in BR Market | 3.0% |
Stable Share Price: G2ME34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine G2ME34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 5,300 | Dan Scavilla | www.globusmedical.com |
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution.
Globus Medical, Inc. Fundamentals Summary
| G2ME34 fundamental statistics | |
|---|---|
| Market cap | R$56.13b |
| Earnings (TTM) | R$591.57m |
| Revenue (TTM) | R$14.47b |
94.9x
P/E Ratio3.9x
P/S RatioIs G2ME34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G2ME34 income statement (TTM) | |
|---|---|
| Revenue | US$2.52b |
| Cost of Revenue | US$819.88m |
| Gross Profit | US$1.70b |
| Other Expenses | US$1.60b |
| Earnings | US$102.98m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.75 |
| Gross Margin | 67.46% |
| Net Profit Margin | 4.09% |
| Debt/Equity Ratio | 10.6% |
How did G2ME34 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/16 10:46 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Globus Medical, Inc. is covered by 26 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Matt Miksic | Barclays |
| Craig Bijou | BofA Global Research |